All In Biotech

Drug Trial Radar · NCT05322473

Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients With Active Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 234 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

234

Actual

Start

Apr 25, 2022

Primary completion

May 9, 2023

Study completion Aug 30, 2023

Sponsor

Lead sponsor
MoonLake Immunotherapeutics AGIndustry
Sponsor type
Industry
First posted
Apr 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • Sonelokimab (M1095)Drug

    randomized treatment; parallel-group

  • AdalimumabDrug

    randomized treatment; parallel-group

  • PlaceboOther

    randomized treatment; parallel-group

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 12Time frame: At Week 12

Locations

57 sites in 7 countries. Site status is shown where the registry gives one.

  • Clinical Site

    Fountain Valley, California

  • Clinical Site

    Los Angeles, California

  • Clinical Site

    Miami, Florida

  • Clinical Site

    Ormond Beach, Florida

  • Clinical Site

    St. Petersburg, Florida

  • Clinical Site

    Tampa, Florida

  • Clinical Site

    Indianapolis, Indiana

  • Clinical Site

    Beverly, Massachusetts

  • Clinical Site

    Boston, Massachusetts

  • Clinical Site

    Omaha, Nebraska

  • Clinical Site

    New York, New York

  • Clinical Site

    Philadelphia, Pennsylvania

  • Clinical Site

    Charleston, South Carolina

  • Clinical Site

    Nashville, Tennessee

  • Clinical Site

    Bellaire, Texas

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Stara Zagora, Bulgaria

  • Clinical Site

    Calgary, Alberta, Canada

  • Clinical Site

    Winnipeg, Manitoba, Canada

  • Clinical Site

    Fredericton, New Brunswick, Canada

  • Clinical Site

    St. John's, Newfoundland and Labrador, Canada

  • Clinical Site

    Hamilton, Ontario, Canada

  • Clinical Site

    London, Ontario, Canada

  • Clinical Site

    Markham, Ontario, Canada

  • Clinical Site

    Newmarket, Ontario, Canada

  • Clinical Site

    Peterborough, Ontario, Canada

  • Clinical Site

    Saskatoon, Saskatchewan, Canada

  • Clinical Site

    Bad Bentheim, Germany

  • Clinical Site

    Berlin, Germany

  • Clinical Site

    Berlin, Germany

  • Clinical Site

    Berlin, Germany

  • Clinical Site

    Bochum, Germany

  • Clinical Site

    Darmstadt, Germany

  • Clinical Site

    Dresden, Germany

  • Clinical Site

    Frankfurt, Germany

  • Clinical Site

    Hamburg, Germany

  • Clinical Site

    Kiel, Germany

  • Clinical Site

    Lübeck, Germany

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.